Skip to content

Study · Randomized controlled trial · n = 66 · 2014

5 results

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.

Ito M, Oishi R, Fukunaga M, Sone T, Sugimoto T, Shiraki M, Nishizawa Y, Nakamura T

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA18 Dec 2013Cited by 25 (Europe PMC)

PMID24345886 (opens in a new tab)PMCIDPMC3923120 (opens in a new tab)DOI10.1007/s00198-013-2596-y (opens in a new tab)PepBankPUB-24345886
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide increased femoral neck and shaft cortical thickness versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide increased cortical thickness at the femoral neck and shaft versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical thickness
    Study

    n = 66

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We found that once-weekly teriparatide increased cortical thickness/cross-sectional area (CSA) and total area, and improved biomechanical properties (i.e., decreasing BR) at the femoral neck and shaft.
    2 context sentences
    Summary · context
    The subjects were a subgroup of a recent, randomly assigned, double-blind study (578 subjects) comparing the anti-fracture efficacy of a once-weekly subcutaneous injection of 56.5 μg teriparatide with placebo (TOWER trial).
    Summary · context
    Sixty-six ambulatory postmenopausal women with osteoporosis were enrolled at 15 study sites having multi-detector row CT, and included women injected with teriparatide (n = 29, 74.2 ± 5.1 years) or with placebo (n = 37, 74.8 ± 5.3 years).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide increased femoral neck and shaft total area versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide increased total area at the femoral neck and shaft versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal area
    Study

    n = 66

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We found that once-weekly teriparatide increased cortical thickness/cross-sectional area (CSA) and total area, and improved biomechanical properties (i.e., decreasing BR) at the femoral neck and shaft.
    2 context sentences
    Summary · context
    The subjects were a subgroup of a recent, randomly assigned, double-blind study (578 subjects) comparing the anti-fracture efficacy of a once-weekly subcutaneous injection of 56.5 μg teriparatide with placebo (TOWER trial).
    Summary · context
    Sixty-six ambulatory postmenopausal women with osteoporosis were enrolled at 15 study sites having multi-detector row CT, and included women injected with teriparatide (n = 29, 74.2 ± 5.1 years) or with placebo (n = 37, 74.8 ± 5.3 years).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide decreased femoral neck and shaft buckling ratio versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide reduced femoral neck and shaft buckling ratio versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBuckling ratio
    Study

    n = 66

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We found that once-weekly teriparatide increased cortical thickness/cross-sectional area (CSA) and total area, and improved biomechanical properties (i.e., decreasing BR) at the femoral neck and shaft.
    2 context sentences
    Summary · context
    The subjects were a subgroup of a recent, randomly assigned, double-blind study (578 subjects) comparing the anti-fracture efficacy of a once-weekly subcutaneous injection of 56.5 μg teriparatide with placebo (TOWER trial).
    Summary · context
    Sixty-six ambulatory postmenopausal women with osteoporosis were enrolled at 15 study sites having multi-detector row CT, and included women injected with teriparatide (n = 29, 74.2 ± 5.1 years) or with placebo (n = 37, 74.8 ± 5.3 years).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide did not change cortical perimeter versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide did not change cortical perimeter compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical perimeter
    Study

    n = 66

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Teriparatide did not change the cortical perimeter.
    2 context sentences
    Summary · context
    The subjects were a subgroup of a recent, randomly assigned, double-blind study (578 subjects) comparing the anti-fracture efficacy of a once-weekly subcutaneous injection of 56.5 μg teriparatide with placebo (TOWER trial).
    Summary · context
    Sixty-six ambulatory postmenopausal women with osteoporosis were enrolled at 15 study sites having multi-detector row CT, and included women injected with teriparatide (n = 29, 74.2 ± 5.1 years) or with placebo (n = 37, 74.8 ± 5.3 years).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide increased femoral neck and shaft cortical cross-sectional area versus placebo.

    In plain wordsIn women with osteoporosis, teriparatide increased cortical cross-sectional area at the femoral neck and shaft versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical cross-sectional area
    Study

    n = 66

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We found that once-weekly teriparatide increased cortical thickness/cross-sectional area (CSA) and total area, and improved biomechanical properties (i.e., decreasing BR) at the femoral neck and shaft.
    2 context sentences
    Summary · context
    The subjects were a subgroup of a recent, randomly assigned, double-blind study (578 subjects) comparing the anti-fracture efficacy of a once-weekly subcutaneous injection of 56.5 μg teriparatide with placebo (TOWER trial).
    Summary · context
    Sixty-six ambulatory postmenopausal women with osteoporosis were enrolled at 15 study sites having multi-detector row CT, and included women injected with teriparatide (n = 29, 74.2 ± 5.1 years) or with placebo (n = 37, 74.8 ± 5.3 years).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.